2019 年年度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年年度报告 2020 年 4 月 1 / 240 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 张沛 | 公务 | 吴涛 | 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张芝庭、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 鉴于子公司沙文生产研发基地项目建设投资资金需求量较大，公司本年度不分配，不转增。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及的未来计划、发展战略 ...

Financial Performance - Operating revenue for the first quarter was CNY 342,993,999, representing a decrease of 19.56% year-on-year[7]. - Net profit attributable to shareholders was CNY 8,677,484, down 63.44% compared to the same period last year[7]. - Basic earnings per share decreased by 50.00% to CNY 0.02 compared to CNY 0.04 in the previous year[7]. - The weighted average return on equity dropped to 0.33%, down 0.60 percentage points from the previous year[7]. - The net profit for Q1 2020 was CNY 11,008,981.12, a decrease of 47.97% compared to CNY 21,158,809.18 in the same period last year[12]. - Total revenue for Q1 2020 was ¥342,993,999.78, a decrease of 19.5% compared to ¥426,384,693.33 in Q1 2019[25]. - Net profit for Q1 2020 was ¥11,008,981.12, a decline of 48.0% from ¥21,158,809.18 in Q1 2019[26]. - The company reported a total comprehensive income of ¥3,607,340.58 for Q1 2020, significantly lower than ¥33,243,253.35 in Q1 2019[26]. - The total comprehensive income for Q1 2020 was a loss of CNY 8,880,376.17, compared to a gain of CNY 10,406,512.58 in Q1 2019[29]. Cash Flow - Cash flow from operating activities showed a net inflow of CNY 14,904,611, a significant decline of 71.69% year-on-year[7]. - The company's cash flow from operating activities decreased by 71.69% to CNY 14,904,611.03, down from CNY 52,642,944.73 in the previous year[12]. - The net cash flow from operating activities in Q1 2020 was CNY 14,904,611.03, down 71.7% from CNY 52,642,944.73 in Q1 2019[32]. - The company reported a significant decrease in cash inflows from operating activities, totaling CNY 368,423,652.45 in Q1 2020, compared to CNY 461,475,742.51 in Q1 2019, a decline of approximately 20.1%[32]. - The net cash flow from operating activities for Q1 2020 was -687,868.75, a decrease of 51% compared to -1,405,475.44 in Q1 2019[36]. - The cash and cash equivalents at the end of Q1 2020 were CNY 552,355,855.66, a decrease from CNY 596,052,428.52 at the beginning of the quarter[33]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,604,498,926, an increase of 1.36% compared to the end of the previous year[7]. - The total assets as of March 31, 2020, were CNY 3,604,498,925.99, compared to CNY 3,556,129,011.94 at the end of 2019[18]. - The total liabilities as of March 31, 2020, were CNY 939,360,580.74, an increase from CNY 894,598,007.27 year-on-year[19]. - Total liabilities for Q1 2020 were 894,598,007.27, remaining consistent with the previous year[41]. - Total assets amounted to approximately $2.03 billion, with current assets at about $219.79 million and non-current assets at approximately $1.81 billion[44]. - Total liabilities were reported at approximately $49.07 million, with current liabilities totaling around $33.51 million and non-current liabilities at about $15.55 million[45]. - The company’s total liabilities and shareholders' equity matched the total assets, confirming a balanced financial position at $2.03 billion[45]. Shareholder Information - The total number of shareholders at the end of the reporting period was 49,531[9]. - The largest shareholder, Guizhou Magic Investment Co., Ltd., held 131,301,620 shares, accounting for 24.59% of the total shares[9]. - The total equity attributable to shareholders as of Q1 2020 was 2,616,230,980.01, consistent with the previous year[41]. Research and Development - Research and development expenses increased by 43.35% to CNY 1,943,360.73 from CNY 1,355,690.42 year-on-year[12]. - Research and development expenses for Q1 2020 were ¥1,943,360.73, an increase from ¥1,355,690.42 in Q1 2019[25]. - The company incurred research and development expenses, although specific figures were not disclosed in the provided data[28]. Government Support and Non-Operating Loss - The company received government subsidies totaling CNY 976,277, which included various forms of support related to the COVID-19 pandemic[9]. - The company reported a significant non-operating loss of CNY 2,587,422 due to donations made in response to the pandemic[9]. - The company anticipates potential losses or significant changes in net profit compared to the previous year due to ongoing challenges[13].

Financial Performance - Operating revenue for the first quarter was CNY 342,993,999, representing a decrease of 19.56% year-on-year[7]. - Net profit attributable to shareholders was CNY 8,677,484, down 63.44% from the same period last year[7]. - Basic earnings per share decreased by 50.00% to CNY 0.02[7]. - The weighted average return on equity fell to 0.33%, a decrease of 0.60 percentage points from the previous year[7]. - The net profit for Q1 2020 was ¥11,008,981.12, a decrease of 47.97% compared to ¥21,158,809.18 in the same period last year[12]. - Total revenue for Q1 2020 was ¥342,993,999.78, a decrease of 19.5% compared to ¥426,384,693.33 in Q1 2019[25]. - Total operating costs for Q1 2020 were ¥326,290,690.37, down 18.3% from ¥399,479,951.62 in Q1 2019[25]. - Net profit for Q1 2020 was ¥11,008,981.12, a decline of 48.0% from ¥21,158,809.18 in Q1 2019[26]. - The company reported a total comprehensive income of ¥3,607,340.58 for Q1 2020, down from ¥33,243,253.35 in Q1 2019[26]. - The net profit for Q1 2020 was a loss of CNY 1,478,735.63, an improvement from a loss of CNY 1,677,931.59 in Q1 2019, reflecting a reduction in losses by approximately 11.9%[29]. - The total comprehensive income for Q1 2020 was a loss of CNY 8,880,376.17, compared to a gain of CNY 10,406,512.58 in Q1 2019[29]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,604,498,926, an increase of 1.36% compared to the end of the previous year[7]. - The total assets as of March 31, 2020, were ¥3,604,498,925.99, compared to ¥3,556,129,011.94 at the end of 2019[18]. - Total assets as of Q1 2020 were 3,556,129,011.94, unchanged from the previous year, indicating stability in asset management[40]. - Total liabilities as of March 31, 2020, were ¥47,062,733.28, down from ¥49,068,273.77 as of December 31, 2019[23]. - Total liabilities stood at 894,598,007.27 in Q1 2020, reflecting a consistent liability structure compared to the previous year[41]. - Total liabilities were reported at approximately $49.07 million, with current liabilities totaling around $33.51 million and non-current liabilities at approximately $15.55 million[45]. Cash Flow - Cash flow from operating activities showed a net inflow of CNY 14,904,611, a significant decline of 71.69% compared to the previous year[7]. - Cash flow from operating activities decreased by 71.69% to ¥14,904,611.03, down from ¥52,642,944.73 in the previous year[12]. - The cash flow from investing activities showed a net outflow of ¥48,309,789.68, a significant increase of 714.33% compared to the previous year[12]. - The net cash flow from operating activities for Q1 2020 was CNY 14,904,611.03, down 71.7% from CNY 52,642,944.73 in Q1 2019[32]. - The company experienced a net cash outflow from investing activities of CNY 48,309,789.46 in Q1 2020, compared to a smaller outflow of CNY 5,932,435.30 in Q1 2019[33]. - The company reported cash inflow from investment activities of 698,852.92 in Q1 2020, with no cash outflow recorded in the same category[36]. Shareholder Information - The total number of shareholders at the end of the reporting period was 49,531[9]. - The largest shareholder, Guizhou Magic Investment Co., Ltd., held 24.59% of the shares, with 131,301,620 shares pledged[9]. - Shareholders' equity reached approximately $1.98 billion, including paid-in capital of about $534.07 million and retained earnings of approximately $225.74 million[45]. Government Support and Non-Operating Losses - The company received government subsidies totaling CNY 976,277, which included various forms of support related to the COVID-19 pandemic[9]. - The company reported a significant non-operating loss of CNY 2,587,422 due to donations made in response to the pandemic[9]. Research and Development - Research and development expenses increased by 43.35% to ¥1,943,360.73 from ¥1,355,690.42 year-on-year[12]. - Research and development expenses for Q1 2020 were ¥1,943,360.73, an increase from ¥1,355,690.42 in Q1 2019[25]. Accounting Standards and Future Outlook - The company executed new revenue and leasing standards starting January 1, 2020, which may impact future financial reporting[38]. - The company implemented the new revenue recognition standard starting January 1, 2020, which did not have a significant impact on financial results or cash flows[46]. - The company has not disclosed any new product developments or market expansion strategies in this report[46]. - The company anticipates potential losses or significant changes in net profit compared to the previous year[13].

2019 年 10 月 1 / 30 2019 年第三季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 30 2019 年第三季度报告 | （税后） | | | | --- | --- | --- | | 所得税影响额 | -137,478.68 | -307,174.56 | ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥911,009,600.51, representing a year-on-year increase of 6.30% compared to ¥857,022,515.73 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥57,149,229.91, a decrease of 2.43% from ¥58,570,939.08 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥56,235,803.84, which is an increase of 15.75% from ¥48,585,691.08 in the same period last year[21]. - The net cash flow from operating activities was ¥67,183,416.47, down 31.18% from ¥97,621,314.18 in the previous year[21]. - The total assets at the end of the reporting period were ¥3,432,042,593.35, an increase of 9.77% from ¥3,126,491,309.12 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased to ¥2,596,433,219.94, a rise of 2.23% from ¥2,539,856,196.66 at the end of the previous year[21]. - The basic earnings per share remained at ¥0.11, unchanged from the previous year[22]. - The weighted average return on net assets decreased by 0.12 percentage points to 2.23% compared to the previous year[22]. Revenue Segmentation - The increase in operating revenue was attributed to a rise in pharmaceutical manufacturing sales by ¥45,595,100, an increase of 8.07%[21]. - The pharmaceutical commerce segment also saw an increase of ¥839,200, representing a growth of 2.87%[21]. - The pharmaceutical manufacturing segment accounted for 67.03% of total revenue during the reporting period[28]. - The pharmaceutical commercial segment accounted for 32.97% of total revenue during the reporting period[28]. Cash Flow and Assets - As of the end of the reporting period, cash and cash equivalents increased by 75.02% to CNY 360,220,096.71, representing 10.49% of total assets[46]. - Accounts receivable decreased by 44.26% to CNY 100,416,203.88, accounting for 2.93% of total assets[46]. - Prepayments increased by 70.61% to CNY 166,596,849.01, making up 4.85% of total assets[46]. - Other receivables rose by 67.11% to CNY 328,416,414.95, which is 9.57% of total assets[46]. - Short-term borrowings amounted to CNY 101,080,000.00, indicating a significant increase[47]. - Tax payable decreased by 68.18% to CNY 15,264,789.57, representing 0.44% of total liabilities[47]. Subsidiary Performance - Revenue from the subsidiary Jinqiao Pharmaceutical was CNY 323.99 million, with a net profit of CNY 14.21 million[51]. - Revenue from the subsidiary Magic Pharmaceutical was CNY 152.41 million, with a net profit of CNY 3.28 million[52]. - Revenue from the subsidiary Baiqiang Pharmaceutical was CNY 394.22 million, with a net profit of CNY 43.47 million[52]. Risks and Challenges - The company faces significant policy risks due to increasing regulatory scrutiny in the pharmaceutical industry, which may lead to a decline in overall drug prices and impact future development[53]. - The company is investing heavily in drug research and development, but faces risks related to regulatory approval processes and potential delays in drug registration[54]. - Rising raw material costs due to supply constraints and regulatory pressures may impact the company's profitability, necessitating improved procurement strategies[63]. Corporate Governance and Compliance - The company has not experienced any major product quality issues but acknowledges the potential risks associated with quality control in the pharmaceutical sector[60]. - The company has committed to maintaining the independence of its actual controller and related parties in business operations[69]. - The company has no major litigation or arbitration matters during the reporting period[72]. - The actual controller and major shareholders maintained a good integrity record without any administrative or criminal penalties related to the securities market during the reporting period[73]. Investment and Development - The company is actively developing the efficacy of the sodium cantharidate series products to solidify its leading position in the anti-tumor field[40]. - The company is advancing the construction of its Sha Wen production and R&D base to upgrade its industrial foundation and promote sustainable development[41]. - The company plans to expand its market presence and invest in new product development to drive future growth[143]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[143]. Financial Reporting and Accounting - The company’s financial statements comply with the enterprise accounting standards, reflecting its financial status and operational results accurately[158]. - The company’s consolidated financial statements include all subsidiaries under its control, ensuring a comprehensive view of its financial performance[165]. - The company recognizes investment income from the difference between the consideration received from disposals and the fair value of remaining equity investments[167].

2019 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年第一季度报告 (修订稿) 2019 年 4 月 1 / 26 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2019 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 张芝庭 | 董事 | 公务 | 张涛涛 | | 段竞晖 | 独立董事 | 公务 | 王强 | 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主 ...

2018 年年度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2018 年年度报告 2019 年 4 月 1 / 214 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 张芝庭 | 公务 | 张涛涛 | | 独立董事 | 段竞晖 | 公务 | 王强 | 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 鉴于子公司沙文生产研发项目建设投资资金需求量较大，公司本年度不分配，不转增。 六、 前瞻性陈述的风险声明 √ ...

2019 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年第一季度报告 2019 年 4 月 1 / 26 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2019 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 张芝庭 | 董事 | 公务 | 张涛涛 | | 段竞晖 | 独立董事 | 公务 | 王强 | 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 ...

2018 年第三季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2018 年第三季度报告 2018 年 10 月 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 21 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,167,050,298.34 3,095,87 ...

2018 年半年度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2018 年半年度报告 2018 年 8 月 1 / 128 2018 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本半年度报告第四节"经营情况讨论与分析"中"二、其他披露事项"部分，详细 描 ...